Please assess the completion status of the following clinical trial:

Trial Title: The Epidemiology of Bleeding and Clotting in Patients Undergoing Heart Transplantation, Coronary Artery Bypass Graft Surgery,or Implantation of Left Ventricular Assist Devices

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent, release of medical information, and HIPAA forms;~2. Age greater than or equal to 18 years;~3. Male, postmenopausal female, or female who may become pregnant but is using adequate contraceptive precautions (defined as oral contraceptive, intrauterine devices, surgical contraception or a combination of a condom and a spermicide), with negative pregnancy test;~4. Admitted to the clinical center at the time of enrollment;~5. Approved and scheduled to undergo one of the following within 24 hours of enrollment:~   * Orthotopic heart transplantation~  * CABG and/or valve surgery on CPB; these patients must have an LV ejection fraction of ≤35%~  * Implantation of a pulsatile LVAD (e.g.Thoratec HeartMate® I LVAD) for destination therapy or bridge to transplantation~  * Implantation of a continuous flow LVAD (e.g. HeartMate® II, DeBakey VAD® or VentrAssist® LVAS) for destination therapy or bridge to transplantation~Exclusion Criteria:~1. History of a platelet disorder;~2. History of a known, or an inherited, or an acquired coagulation disorder in the study subject;~3. Stroke within 30 days prior to enrollment;~4. Allergy to heparin or protamine;~5. Participation in a clinical investigational intervention trial, with the exception of an investigational VAD trial, at the time of enrollment;~6. Received investigational intervention within 30 days of enrollment, with the exception of an investigational VAD trial

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Group I: Cardiopulmonary Bypass + Heart Transplantation (Type: None): CPB for orthotopic heart transplantation (excluding any patients with VADs)
- Group II: Cardiopulmonary Bypass + Pulsatile LVAD (Type: None): CPB for implantation of a Thoratec HeartMate I LVAD (for destination therapy or bridge to transplantation).
- Group III: Cardiopulmonary Bypass + Continuous Flow LVAD (Type: None): CPB for implantation of an axial flow or centrifugal flow LVAD (for destination therapy or bridge to transplantation) (e.g. HeartMate II, DeBakey VAD or VentraAssist LVAS)
- Group IV: Cardiopulmonary Bypass + CABG Surgery (Type: None): CPB for CABG surgery

Based on this trial design, predict the completion outcome and termination type (if applicable).